TRCT
FHTX icon

Tower Research Capital (TRC)’s Foghorn Therapeutics FHTX Stock Holding History

Tower Research Capital (TRC)’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16K Sell
3,282
-13
-0.4% -$58 ﹤0.01% 3734
2026
Q1 		$15.8K Buy
3,295
+1,222
+59% +$6.71K ﹤0.01% 3653
2025
Q4 		$11.2K Sell
2,073
-431
-17% -$1.95K ﹤0.01% 3635
2025
Q3 		$12.2K Sell
2,504
-6,709
-73% -$35.6K ﹤0.01% 3805
2025
Q2 		$43.3K Buy
9,213
+5,323
+137% +$22.2K ﹤0.01% 3094
2025
Q1 		$14.2K Buy
3,890
+1,786
+85% +$8.14K ﹤0.01% 3308
2024
Q4 		$9.93K Buy
2,104
+683
+48% +$4.98K ﹤0.01% 3857
2024
Q3 		$13.2K Sell
1,421
-8,739
-86% -$63.3K ﹤0.01% 3533
2024
Q2 		$58.4K Buy
10,160
+9,766
+2,479% +$58.2K ﹤0.01% 2976
2024
Q1 		$2.64K Sell
394
-1,133
-74% -$6.29K ﹤0.01% 5004
2023
Q4 		$9.85K Sell
1,527
-3,394
-69% -$14.6K ﹤0.01% 4338
2023
Q3 		$24.6K Buy
4,921
+3,692
+300% +$28.5K ﹤0.01% 3191
2023
Q2 		$8.65K Sell
1,229
-1,135
-48% -$7.94K ﹤0.01% 4397
2023
Q1 		$15K Buy
2,364
+1,112
+89% +$7.28K ﹤0.01% 3781
2022
Q4 		$8K Sell
1,252
-2,435
-66% -$18.4K ﹤0.01% 4387
2022
Q3 		$31K Buy
3,687
+1,767
+92% +$22.7K ﹤0.01% 3574
2022
Q2 		$26K Buy
1,920
+1,026
+115% +$13.2K ﹤0.01% 3509
2022
Q1 		$14K Sell
894
-840
-48% -$11.5K ﹤0.01% 3884
2021
Q4 		$39K Buy
1,734
+913
+111% +$13.1K ﹤0.01% 2971
2021
Q3 		$11K Sell
821
-578
-41% -$6.4K ﹤0.01% 4218
2021
Q2 		$15K Sell
1,399
-568
-29% -$6.19K ﹤0.01% 4122
2021
Q1 		$26K Buy
1,967
+1,529
+349% +$25.1K ﹤0.01% 3678
2020
Q4 		$9K Buy
+438
New +$8.39K ﹤0.01% 4379

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Tower Research Capital (TRC)'s FHTX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Foghorn Therapeutics (FHTX) stake by 0.39% in Q2 2026, selling an estimated $58 and leaving 3,282 shares worth $16K. The position accounts for ﹤0.01% of the portfolio, ranked #3734.

Tower Research Capital (TRC) first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $58.4K in Q2 2024. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Tower Research Capital (TRC) held 3,282 shares of Foghorn Therapeutics worth $16K as of Q2 2026.
  • Tower Research Capital (TRC) sold 13 Foghorn Therapeutics shares in Q2 2026, an estimated $58.
  • Foghorn Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3734 holding.
  • Tower Research Capital (TRC) first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Tower Research Capital (TRC)'s Foghorn Therapeutics position peaked at $58.4K in Q2 2024.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.